Morgan Stanley’s Zenas BioPharma ZBIO Stock Holding History

Morgan Stanley’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.43M	Buy	134,979 +41,583	+45%	+$827K	﹤0.01%	4484
2026 Q1	$1.83M	Sell	93,396 -34,939	-27%	-$784K	﹤0.01%	4823
2025 Q4	$4.66M	Buy	128,335 +39,602	+45%	+$1.3M	﹤0.01%	4233
2025 Q3	$1.97M	Sell	88,733 -35,568	-29%	-$579K	﹤0.01%	4800
2025 Q2	$1.2M	Buy	124,301 +46,391	+60%	+$452K	﹤0.01%	5004
2025 Q1	$615K	Sell	77,910 -280,302	-78%	-$2.19M	﹤0.01%	5241
2024 Q4	$2.93M	Buy	358,212 +307,162	+602%	+$4.79M	﹤0.01%	4420
2024 Q3	$864K	Buy	+51,050	New	+$918K	﹤0.01%	5124

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $242M AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Morgan Stanley's ZBIO Position: Q2 2026 in Review

Morgan Stanley increased its Zenas BioPharma (ZBIO) stake by 45% in Q2 2026, buying an estimated $827K and bringing the position to 134,979 shares worth $3.43M. The position accounts for ﹤0.01% of the portfolio, ranked #4484.

Morgan Stanley first reported a position in ZBIO in Q3 2024 and has held it in 8 quarters since. The position peaked at $4.66M in Q4 2025. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

Morgan Stanley held 134,979 shares of Zenas BioPharma worth $3.43M as of Q2 2026.
Morgan Stanley bought 41,583 Zenas BioPharma shares in Q2 2026, an estimated $827K.
Zenas BioPharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4484 holding.
Morgan Stanley first reported a position in Zenas BioPharma in Q3 2024 and has held it in 8 quarters since.
Morgan Stanley's Zenas BioPharma position peaked at $4.66M in Q4 2025.
144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.